Actavis Must Withdraw Opana ER Generic Four Years After Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Court finds Actavis infringed two Endo patents, judge to decide whether to award damages. Actavis' non-crush-resistant generic has impeded sales of Endo's newer crush-resistant version.
You may also be interested in...
A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen
Biogen has been granted new US patents for Tecfidera after generics already launched. It's unclear how Biogen will proceed but management could shed more light on the matter during the first quarter call.
FDA Rejects Endo’s Deadline On Opana ER Petition; Impax Product May Become New RLD
Endo files suit against FDA seeking preliminary injunction to require FDA to say whether Endo’s withdrawal of non-crush resistant Opana ER was for safety reasons; FDA contends it has until May 10, 2013 to make this decision.
Endo Seeks To Block Generics Of Opana ER That Are Not Crush-Resistant
Endo citizen petition asks FDA to determine that the company’s old formulation was withdrawn for safety reasons and to decline approval of ANDAs of that formulation; Purdue Pharma files third OxyContin citizen petition.